|
| Clinical efficacy of observation new Shenkangning capsule in the treatment of early stage hypertensive nephropathy |
| Hits 1832 Download times 1475 Received:March 24, 2017 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2017.08.05 |
| Key Words
new Shenkangning capsule;early hypertensive nephropathy;urinary albumin;serum cystatin C |
| Author Name | Affiliation | E-mail | | ZHOU Wen-jun | Department of Nephrology, Affiliated Hospital of Tianjin Institute of Traditional Chinese Medicine, Tianjin 300120, China | | | SUN Lan-yun | Department of Nephrology, Affiliated Hospital of Tianjin Institute of Traditional Chinese Medicine, Tianjin 300120, China | sunlanyun257@sina.com |
|
| Abstract
|
| [Objective] To observe the clinical effect of the new new Shenkangning capsule in the treatment of early hypertensive nephropathy.[Methods] The essential hypertension patients with early renal injury in 60 cases, using random parallel control principle, divided into treatment group and control group with 30 cases in each group, two groups were treated with ACEI/ARB or calcium antagonist antihypertensive therapy, the treatment group at the same time with the Corelle kidney capsule, 4 pills, 3 times daily for 1 months the 1 course of treatment, after 3 courses of induction and the total scores of symptoms before and after treatment of urinary albumin and serum cystatin C (Cys-C) index changes, and statistical analysis.[Results] The treatment group in improving traditional Chinese medicine symptoms, urinary albumin (mAlb), serum Cys-C index changes were better than the control group (P<0.05).[Conclusion] The combination of new Shenkangning capsule can improve the clinical symptoms of early hypertensive nephropathy, reduce urinary albumin and serum cystatin index may be associated with improved renal ischemia, hypoxia, reduce glomerular sclerosis, delaying renal damage in patients with essential hypertension. |
|
|
|
|
|
|
|
